Yu Guangyan, Peng Xin, Gao Min, Ye Peng, Ge Na, Jia Mengqi, Li Bingyu, Tang Zunan, Hu Leihao, Zhang Wenbo
Department of Oral & Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Feb 18;57(1):1-6. doi: 10.19723/j.issn.1671-167X.2025.01.001.
Salivary gland tumor is one of the most common tumors in oral and maxillofacial regions. The diagnosis and treatment of salivary gland tumors had been a clinical characteristic project in Peking University School and Hospital of Stomatology since long time ago. Here we introduced the research progress in diagnosis and treatment of salivary gland tumors during the past 10 years. Among 7 190 cases of salivary gland tumors treated in this institution, 4 654 cases (64.7%) were benign, and 2 536 (35.3%) were malignant, with benign ∶ malignant ratio of 1.84 ∶ 1. Parotid was the most common location, followed by minor salivary gland and submandibular gland, while sublingular gland tumor was seldom seen. The proportion of minor salivary gland tumor was relatively high. Among 1 874 cases with primary malignant tumors, the cases with T3 and stage Ⅲ accounted for only 9.6% and 10.3%, respectively, which indicated that there was shortcoming in the T classification and clinical stage formulated by Union for International Cancer Control (UICC), and further revision was required. The 5, 10, and 15 year survival rates of 1 637 cases with postoperative follow-up were 93.1%, 87.2% and 79.3%, respectively, which were much higher than those we reported 30 years ago. The improvement of treatment results was related to more widely used combined treatment with surgery and postoperative radiotherapy, and the increase in patients with early stage. Adenoid cystic carcinoma was the malignant tumor with high rate of distant metastasis. The 5 and 10 year survival rates of the patients with pulmonary metastasis were 76.2% and 51.8%, respectively, which indicated that the pulmonary metastatic carcinomas developed slowly. Recurrent rate of carcinoma ex pleomorphic adenoma was 46.7% after single treatment of sur-gery, while it decreased to 27.5% after combined theraphy with surgery and radiotherapy, indicating that postoperative radiotheraphy could reduce the recurrent rate effectively. The normal myoepithelial cells had the inhibiting role in the invasion and metastasis of carcinoma ex pleomorphic adenoma. The evaluation of integrity of myoepithelial cells surrounding the tumor mass is helpful to understand the invasiveness of the tumors. The new surgical modalities such as extracapsular resection and partial sialoadenectomy were used in treatment of benign tumors of parotid gland and submandibular gland with advantages of decreased tissue damage and preservation of glandular function. Application of digital surgical techniques such as mixed reality combined with surgical navigation and real-time three-dimensional holograms in the surgical treatment of parotid gland tumors showed the benifits of more safety and precision, and less tissue da-mage.
涎腺肿瘤是口腔颌面部最常见的肿瘤之一。长期以来,涎腺肿瘤的诊断与治疗一直是北京大学口腔医学院的临床特色项目。在此,我们介绍过去10年涎腺肿瘤诊断与治疗的研究进展。在本机构治疗的7190例涎腺肿瘤病例中,4654例(64.7%)为良性,2536例(35.3%)为恶性,良性与恶性比例为1.84∶1。腮腺是最常见的发病部位,其次是小涎腺和下颌下腺,而舌下腺肿瘤少见。小涎腺肿瘤所占比例相对较高。在1874例原发性恶性肿瘤病例中,T3期和Ⅲ期病例分别仅占9.6%和10.3%,这表明国际癌症控制联盟(UICC)制定的T分类和临床分期存在不足,需要进一步修订。1637例术后随访病例的5年、10年和15年生存率分别为93.1%、87.2%和79.3%,远高于我们30年前报告的生存率。治疗效果的提高与手术联合术后放疗的更广泛应用以及早期患者数量的增加有关。腺样囊性癌是远处转移率较高的恶性肿瘤。肺转移患者的5年和10年生存率分别为76.2%和51.8%,这表明肺转移癌发展缓慢。多形性腺瘤癌变单纯手术治疗后的复发率为46.7%,而手术联合放疗后的复发率降至27.5%,表明术后放疗可有效降低复发率。正常肌上皮细胞对多形性腺瘤癌变的侵袭和转移具有抑制作用。评估肿瘤周围肌上皮细胞的完整性有助于了解肿瘤的侵袭性。诸如包膜外切除和部分涎腺切除术等新的手术方式被用于治疗腮腺和下颌下腺良性肿瘤,具有减少组织损伤和保留腺体功能的优点。数字外科技术如混合现实结合手术导航和实时三维全息图在腮腺肿瘤手术治疗中的应用显示出更安全、精确且组织损伤更小的优势。